Invention Grant
- Patent Title: 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors
-
Application No.: US16129867Application Date: 2018-09-13
-
Publication No.: US10336719B2Publication Date: 2019-07-02
- Inventor: Weichun Chen , Ebere F Igboko , Xichen Lin , Hongfu Lu , Feng Ren , Paul Bryan Wren , Zhongmiao Xu , Ting Yang , Lindong Zhu
- Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
- Applicant Address: GB Brentford, Middlesex
- Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee Address: GB Brentford, Middlesex
- Agent Leah M. Octavio; Fang Qian
- Priority: WOPCT/CN2014/000545 20140529; WOPCT/CN2014/083380 20140731; WOPCT/CN2015/077947 20150430
- Main IPC: C07D307/18
- IPC: C07D307/18 ; C07D241/04 ; C07D309/08 ; C07C317/50 ; C07C317/42 ; C07C311/47 ; C07D305/06 ; C07D213/34 ; C07D295/135 ; C07D211/54 ; C07D207/10 ; C07D487/04 ; C07D471/04 ; C07D239/26 ; C07D233/64
Abstract:
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
Public/Granted literature
- US20190010135A1 Novel Compounds Public/Granted day:2019-01-10
Information query
